Overview

Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate efficacy and safety of initial combination therapy with Gemigliptin 50mg q.d and Metformin q.d compared with either monotherapy in treatment naïve patients with type 2 diabetes, In other words, to proof superiority of initial combination therapy with Gemigliptin and Metformin than each monotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

LG Life Sciences

Treatments:

Metformin